GE Healthcare and M+W Group Form Strategic Alliance in Vaccines, Insulin and Biopharmaceuticals

CHALFONT ST GILES, England & STUTTGART, Germany--(BUSINESS WIRE)--GE Healthcare, the healthcare business of GE (NYSE: GE) and M+W Group, a leading global engineering, construction and project management company, announced today that the companies have formed a strategic alliance aimed at overcoming the lack of key biopharmaceuticals, especially in emerging nations. The alliance, which will combine GE Healthcare’s expertise in technologies for biopharmaceutical manufacture with M+W Group’s global capabilities in bio-engineering and construction, will assist countries worldwide to become self-sufficient in the manufacture of vital biopharmaceuticals such as vaccines, insulin and biosimilars. Together, the companies will offer governments and pharmaceutical companies an integrated, cost-competitive “turn-key” approach for the construction of biopharmaceutical manufacturing plants, to help meet the rapidly increasing worldwide demand for these potentially life-saving treatments. The alliance between the two companies aligns with GE’s healthymagination initiative, which focuses on reducing cost, increasing access and improving quality in healthcare.